Cancer Survivor Clinical Trial
Official title:
Ginseng as an Intervention to Decrease Cancer-Related Fatigue in Post-Treatment Cancer Survivors: A Randomized Controlled Pilot Study
Verified date | March 2022 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized pilot trial studies how well North American ginseng extract AFX-2 (ginseng) works in decreasing cancer-related fatigue after treatment in cancer survivors. Ginseng may decrease fatigue in people who were treated for cancer.
Status | Completed |
Enrollment | 2 |
Est. completion date | February 22, 2021 |
Est. primary completion date | May 13, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologic or cytologic proven breast cancer or colon cancer (stage I, II or III) - Treated with chemotherapy and surgery - Treatment has been completed (except hormone therapy) for >= 90 days prior to registration - No known evidence of disease - Men or women with a history of CRF as defined by a score >= 4 on the numeric analogue scale (0 ? 10) (Eligibility Question Fatigue Scale) - Presence of CRF >= 30 days prior to registration - Hemoglobin >= 11.0 g/dL obtained =< 180 days prior to registration - Serum glutamic-oxaloacetic transaminase (SGOT) =< 1.5 x upper limit of normal (ULN) obtained =< 180 days prior to registration - Creatinine =< 1.2 X ULN obtained =< 180 days prior to registration - Ability to complete questionnaire(s) in English by themselves or with assistance - Provide written informed consent - Willing to return to enrolling institution for follow-up of the study and optional crossover (if applicable) - Willing to provide blood samples for correlative research purposes - Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only - CROSSOVER RE-REGISTRATION - INCLUSION CRITERIA - Treatment cannot begin prior to re-registering to the crossover phase and will ideally begin =< 7 days after registration for the crossover phase Exclusion Criteria: - Hypersensitivity to ginseng - Use of ginseng capsules for fatigue, within the last 12 months - Uncontrolled hypertension >= 2 times as noted in medical history (diastolic blood pressure > 100, systolic > 160) =< 90 days prior to registration - Currently using any other pharmacologic agent to specifically treat fatigue including psychostimulants, antidepressants, etc., although antidepressants used to treat items other than fatigue (such as hot flashes) are allowed if the patient has been on a stable dose for >= 30 days prior to registration and plans to continue for >= 30 days after registration; erythropoietin agents to treat anemia are allowed - Known brain metastasis or primary central nervous system (CNS) malignancy - Chronic oral or intravenous systemic steroid use (defined as being used on a regular basis or who have a problem that has required ongoing use of steroids in the last 180 days for greater than 7 days) - Diabetes (defined by being on oral hypoglycemics or insulin) - Psychiatric disorder such as severe depression, manic depressive disorder, obsessive compulsive disorder or schizophrenia; (defined per medical history) - Major surgery =< 28 days prior to registration - Any of the following: - Pregnant women - Nursing women - Women of childbearing potential who are unwilling to employ adequate contraception - Treatable causes of fatigue have not been ruled out, at least by history and exam criteria, by the treating provider, such as uncontrolled pain, hypothyroidism, or insomnia; NOTE: if these are considered to be the primary cause for the patient?s fatigue then the patient is not eligible for this trial - Patients with pain requiring opioid pain medication; NOTE: over the counter analgesics such as Tylenol or ibuprofen are allowed - New use of Ambien and/or other benzodiazepines =< 30 days prior to registration - New use of sleep aids including melatonin =< 30 days prior to registration - Use of full anticoagulant doses of coumadin or heparin (exception: 1 mg/day of coumadin for preventing catheter clots is allowed) - Use of monoamine oxidase inhibitors (MAOI) inhibitors - Patients scoring greater than 4 on a 0 to 10 scale with regard to sleep troubles or pain - Patients planning to start any type of cancer therapy during the 8 week, double blind, course of the study, once randomized on the study - Patients with malnutrition, active infection, significant pulmonary disease and cardiovascular disease as determined by the physician as they could impact fatigue - Use of any over the counter herbal/dietary supplement marketed for fatigue or energy (for example, products containing any type of ginseng, Rhodiola rosea, high doses of caffeine, guarana, or anything called an ?adaptogen?) - Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm - History of myocardial infarction =< 180 days prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmia |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Arizona | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in inflammation biomarkers (adiponectin, cortisol, IL-6) | Cytokine levels and cortisol slopes will be described for the sample as a whole at baseline and at 28 days using means and frequencies. Relationships using Spearman correlation will be performed on fatigue measures, mood, and cytokine levels and cortisol slopes as well as evening cortisol levels at baseline. Baseline fatigue scores on the linear analogue scale will then be grouped into a dichotomous variable, (4 to 7 versus 8 to 10) to evaluate whether differences in cortisol and cytokine expression exist based on fatigue severity, using chi square analysis. | Baseline up to day 84 | |
Primary | Change in general subscale of the Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF) | Will be evaluated by taking the change from baseline in the general subscale of the MFSI-SF and comparing the two arms by a two-sample, two-sided t-test. If there is evidence of non-normality (via Shapiro-Wilk testing), a non-parametric procedure such as Wilcoxon rank sum will be used. Graphical procedures will include stream plots of individual patient scores and plots of average values over time for each treatment group. Supplemental tests on endpoints (paired t-test for continuous/ordinal data; McNemar?s test for binary data; and Bowker?s test for categorical data) will be utilized to deter | Baseline up to day 56 | |
Secondary | Change in MFSI-SF emotional subscale | Will be evaluated by taking the change from baseline in the general subscale of the MFSI-SF and comparing the two arms by a two-sample, two-sided t-test. If there is evidence of non-normality (via Shapiro-Wilk testing), a non-parametric procedure such as Wilcoxon rank sum will be used. Graphical procedures will include stream plots of individual patient scores and plots of average values over time for each treatment group. Supplemental tests on endpoints (paired t-test for continuous/ordinal data; McNemar?s test for binary data; and Bowker?s test for categorical data) will be utilized to deter | Baseline up to day 56 | |
Secondary | Change in MFSI-SF general subscale | Will be evaluated by taking the change from baseline in the general subscale of the MFSI-SF and comparing the two arms by a two-sample, two-sided t-test. If there is evidence of non-normality (via Shapiro-Wilk testing), a non-parametric procedure such as Wilcoxon rank sum will be used. Graphical procedures will include stream plots of individual patient scores and plots of average values over time for each treatment group. Supplemental tests on endpoints (paired t-test for continuous/ordinal data; McNemar?s test for binary data; and Bowker?s test for categorical data) will be utilized to deter | Baseline up to day 56 | |
Secondary | Change in MFSI-SF mental subscale | Will be evaluated by taking the change from baseline in the general subscale of the MFSI-SF and comparing the two arms by a two-sample, two-sided t-test. If there is evidence of non-normality (via Shapiro-Wilk testing), a non-parametric procedure such as Wilcoxon rank sum will be used. Graphical procedures will include stream plots of individual patient scores and plots of average values over time for each treatment group. Supplemental tests on endpoints (paired t-test for continuous/ordinal data; McNemar?s test for binary data; and Bowker?s test for categorical data) will be utilized to deter | Baseline up to day 56 | |
Secondary | Change in MFSI-SF physical subscale | Will be evaluated by taking the change from baseline in the general subscale of the MFSI-SF and comparing the two arms by a two-sample, two-sided t-test. If there is evidence of non-normality (via Shapiro-Wilk testing), a non-parametric procedure such as Wilcoxon rank sum will be used. Graphical procedures will include stream plots of individual patient scores and plots of average values over time for each treatment group. Supplemental tests on endpoints (paired t-test for continuous/ordinal data; McNemar?s test for binary data; and Bowker?s test for categorical data) will be utilized to deter | Baseline up to day 56 | |
Secondary | Change in MFSI-SF vigor subscale | Will be evaluated by taking the change from baseline in the general subscale of the MFSI-SF and comparing the two arms by a two-sample, two-sided t-test. If there is evidence of non-normality (via Shapiro-Wilk testing), a non-parametric procedure such as Wilcoxon rank sum will be used. Graphical procedures will include stream plots of individual patient scores and plots of average values over time for each treatment group. Supplemental tests on endpoints (paired t-test for continuous/ordinal data; McNemar?s test for binary data; and Bowker?s test for categorical data) will be utilized to deter | Baseline up to day 56 | |
Secondary | Change in the single item numeric analogue fatigue question | Analysis will involve a t-test and Wilcoxon rank sum procedures (as appropriate). | Baseline up to day 56 | |
Secondary | Fatigue as measured by the National Institutes of Health (NIH) Patient-Reported Outcomes Measurement Information System (PROMIS) score | Analysis will involve a t-test and Wilcoxon rank sum procedures (as appropriate). | At day 28 | |
Secondary | Fatigue as measured by the NIH PROMIS score | Analysis will involve a t-test and Wilcoxon rank sum procedures (as appropriate). | At day 56 | |
Secondary | Incidence of adverse events as reported by the patient in a Ginseng Symptom Experience Diary | Any other possible side effects are recorded in the diary and assessed through nurse phone calls using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Descriptive statistics of frequency (percentage) will be used to summarize adverse event (AE) incidence and severity as measured by the CTCAE version 4.0 for each randomized arm separately. Toxicity data and other incidence rate-based endpoints will be compared across treatment groups using chi-square testing. Binomial confidence intervals for toxicity incidence rates will be constructed for each treatment group. The Gins | Up to day 56 | |
Secondary | Perceived treatment efficacy as measured by the Subject Global Impression of Change | Analysis will involve a t-test and Wilcoxon rank sum procedures (as appropriate). Descriptive statistics will be used to summarize the Global Impression of Change. | At 4 weeks | |
Secondary | Perceived treatment efficacy as measured by the Subject Global Impression of Change | Analysis will involve a t-test and Wilcoxon rank sum procedures (as appropriate). Descriptive statistics will be used to summarize the Global Impression of Change. | At 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02235051 -
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
|
N/A | |
Completed |
NCT01439945 -
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Completed |
NCT01641068 -
Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms
|
N/A | |
Not yet recruiting |
NCT05403671 -
Fit for Everyday Life - Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer
|
N/A | |
Completed |
NCT00246818 -
Effect of Tai Chi Vs. Structured Exercise on Physical Fitness and Stress in Cancer Survivors
|
Phase 2 | |
Completed |
NCT02559557 -
Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects
|
N/A | |
Completed |
NCT00956475 -
Quality of Life in Younger Leukemia and Lymphoma Survivors
|
Phase 1 | |
Completed |
NCT02032121 -
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors
|
N/A | |
Completed |
NCT00932997 -
Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors
|
N/A | |
Completed |
NCT02566408 -
Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity
|
N/A | |
Completed |
NCT02985411 -
Harvest for Health in Older Cancer Survivors
|
N/A | |
Completed |
NCT00915889 -
Psychosocial Support for African-American, Latina-American, or European-American Cervical Cancer Survivors
|
N/A | |
Completed |
NCT02518308 -
Mindfulness Intervention in Reducing Anxiety in Patients Who Have Been Treated for Gynecologic Cancer
|
N/A | |
Completed |
NCT03307044 -
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
|
N/A | |
Terminated |
NCT03781778 -
Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors
|
Phase 2 | |
Completed |
NCT03520283 -
Systems Support Mapping in Guiding Self-Management in Stage I-III Colorectal Cancer Survivors
|
N/A | |
Completed |
NCT02662335 -
Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT01347970 -
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial
|
Phase 2 | |
Completed |
NCT00713505 -
Educational and Skills Training Program for Parents of Childhood Cancer Survivors Who Have Neurobehavioral Dysfunction
|
N/A |